Forest strives to positively impact the health and quality of life of patients through the development of innovative prescription drug therapies.
01.19.2010 - Forest Laboratories, Inc. Reports Fiscal Third Quarter 2010 Earnings Per Share of $0.69, Including One-Time Charges Totaling $0.28 Per Share
01.07.2010 - Forest and Almirall Announce Positive Results from the ACCORD COPD I Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)
01.04.2010 - Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2010 Third Quarter Earnings